John Paulson is an American hedge fund manager and billionaire who founded the New York-based investment management firm Paulson & Co. in 1994. Paulson has most recently added 18,000,000 shares of Teva Pharmaceutical Industries (TEVA, Financial), a 746.48% increase in his holding. Paulson & Co. have also bought 2,938,500 shares of Perrigo Co. PLC (PRGO, Financial) and 7,007,346 shares of CIT Group Inc. (CIT, Financial).
Teva Pharmaceutical Industries was incorporated in Israel on Feb. 13, 1944. The company manufactures generic pharmaceutical products.Â
Teva Pharmaceutical is also traded in Mexico, Germany and Switzerland has a market cap of $50.79 billion, a P/E ratio of 28.48, a P/S ratio of 2.54 and a dividend yield of 2.31%.
Below is a Peter Lynch chart for Teva:
Paulson & Co. also bought 2,938,500 shares of Perrigo Industries, also traded in Israel and Germany. The company was incorporated under the laws of Ireland on June 28, 2013. The company develops, manufactures and distributes over the counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.
Perrigo Industries has a market cap of $22.25 billion, a P/E ratio of 149.72, a P/S ratio of 4.26 and a dividend yield of 0.32%.
Below is a Peter Lynch chart for Perrigo:
Paulson & Co. also bought 7,007,346 new share holdings in CIT Group Inc., which is also traded in Germany. CIT Group was originally incorporated in Delaware on March 12, 2001 as T-Sub Inc. The company provides financing, leasing and advisory services principally to middle market companies in industries primarily in North America, and equipment financing and leasing solutions to the transportation industry worldwide.
CIT Group has a market cap of $8.34 billion, a P/E ratio of 6.70, a P/S ratio of 2.82 and a 1.45% dividend yield.
Below is a Peter Lynch chart for CIT Group:
Â
We can see from these movements that Paulson likes the pharmaceutical industry after buying and adding a combined 20,061,500 shares of TEVA and PRGO.
Cheers to your investment success.
